Replies to post #180783 on Biotech Values

[jq1234]

>> Targacept has reported 13 consecutive trial failures covering 6 distinct indications and 6 distinct drugs. Surely, a record in drug development futility that may never be matched.

Well, you have to give them credit for running randomized trials, mostly forced upon them by indications they chose to work on. To break their streak, they could have chosen to take one short cut by running one single arm trial that wouldn't be considered failure.

[DewDiligence]

Great compilation! TRGT has a helluva track record for futility, but at least they didn’t kill anybody, which is more than can be said for their progenitor company.

[DewDiligence]

Catalyst Biosciences reverse-merges into TRGT public shell:

http://finance.yahoo.com/news/targacept-catalyst-biosciences-enter-definitive-233400776.html

Targacept, Inc. (TRGT) and Catalyst Biosciences, Inc., a privately held biopharmaceutical company, jointly announced today that they have entered into a definitive agreement to merge the two companies. The combined entity, to be named Catalyst Biosciences, Inc., is expected to create a financially strong company to harness the catalytic power of engineered human proteases to develop next-generation biopharmaceuticals with improved efficacy and therapeutic index to treat major diseases.

The ticker symbol will change from TRGT to CBIO in due course.

CC at 8:30a.m. ET tomorrow.

[DewDiligence]

Refreshingly honest PR header from TRGT:

http://finance.yahoo.com/news/targacept-announces-negative-top-line-123000914.html

p.s. I realize this TRGT is not the same company following the reverse merger.